Group 1 for Prolonged Air Leak

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prolonged Air Leak
Oral Antibiotics-Close Monitoring - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether giving oral antibiotics and making phone calls to check on patients' chest tubes and valves helps them recover better than the standard of care.

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 30 days post discharge

30 days post discharge
Change in empyema in patient's discharging with an indwelling chest tube and valve.
Change of 30-day readmission in patient's discharging with an indwelling chest tube and valve.

Trial Safety

Trial Design

2 Treatment Groups

Group 1
1 of 2
Group 2
1 of 2

Active Control

560 Total Participants · 2 Treatment Groups

Primary Treatment: Group 1 · No Placebo Group · N/A

Group 1
Other
ActiveComparator Group · 1 Intervention: Oral Antibiotics-Close Monitoring · Intervention Types: Other
Group 2
Other
ActiveComparator Group · 1 Intervention: Standard of Care · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days post discharge

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,896 Previous Clinical Trials
3,698,761 Total Patients Enrolled
K. Robert Shen, MDPrincipal InvestigatorMayo Clinic

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
An individual who is 18 years of age or older.
Most people are either male or female
A patient was discharged from the hospital with a chest tube and valve in place.
Subject can understand what the study is about and provide consent that is knowledgeable about the study.
You have been referred to a thoracic surgeon for consultation.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: November 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.